Literature DB >> 15559053

Epidemiology, biologic behavior, and natural history of mesothelioma.

Lambros Zellos1, David C Christiani.   

Abstract

Malignant pleural mesothelioma has a well described natural history but poorly defined pathogenesis. It is strongly associated with asbestos exposure. A predominantly locally invasive disease, the success of more aggressive life-prolonging therapies has increased the potential for the development of distant metastases in survivors. Recently described new risk factors may increase the incidence of this disease in future generations, underscoring the need for a more in-depth understanding of its pathobiology. This article reviews the current body of knowledge about the occurrence, distribution, presentation, and natural history of malignant pleural mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15559053     DOI: 10.1016/j.thorsurg.2004.06.011

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  22 in total

1.  Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.

Authors:  Marco Trovo; Davide Franceschini; Carlo Furlan; Francesca Pietrobon; Stefano Vagge; Eleonora Farina; Alberto Revelant; Luca Visani; Virginia Maragna; Giuseppe Parisi; Vieri Scotti
Journal:  Radiol Med       Date:  2019-04-08       Impact factor: 3.469

2.  Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.

Authors:  Mehmet Bayram; Isa Dongel; Ali Akbaş; Ismail Benli; Muhammed Emin Akkoyunlu; Nur Dilek Bakan
Journal:  Lung       Date:  2013-10-30       Impact factor: 2.584

3.  3-O-Methylfunicone, a metabolite produced by Penicillium pinophilum, modulates ERK1/2 activity, affecting cell motility of human mesothelioma cells.

Authors:  E Buommino; I Paoletti; A De Filippis; R Nicoletti; M L Ciavatta; S Menegozzo; M Menegozzo; M A Tufano
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

4.  Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.

Authors:  Lauren E Rosen; Theodore Karrison; Vijayalakshmi Ananthanarayanan; Alexander J Gallan; Prasad S Adusumilli; Fouad S Alchami; Richard Attanoos; Luka Brcic; Kelly J Butnor; Françoise Galateau-Sallé; Kenzo Hiroshima; Kyuichi Kadota; Astero Klampatsa; Nolween Le Stang; Joerg Lindenmann; Leslie A Litzky; Alberto Marchevsky; Filomena Medeiros; M Angeles Montero; David A Moore; Kazuki Nabeshima; Elizabeth N Pavlisko; Victor L Roggli; Jennifer L Sauter; Anupama Sharma; Michael Sheaff; William D Travis; Wickii T Vigneswaran; Bart Vrugt; Ann E Walts; Melissa Y Tjota; Thomas Krausz; Aliya N Husain
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

5.  The application of cold-plasma coagulation on the visceral pleura results in a predictable depth of necrosis without fistula generation.

Authors:  Martin Hoffmann; Anita Ulrich; Erik Schloericke; Stefan Limmer; Jens Karsten Habermann; Heike Wolken; Hans-Peter Bruch; Peter Kujath
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-12-22

6.  Residential proximity to naturally occurring asbestos and mesothelioma risk in California.

Authors:  Xue-lei Pan; Howard W Day; Wei Wang; Laurel A Beckett; Marc B Schenker
Journal:  Am J Respir Crit Care Med       Date:  2005-06-23       Impact factor: 21.405

7.  FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.

Authors:  Victor H Gerbaudo; Marcelo Mamede; Beatrice Trotman-Dickenson; Hiroto Hatabu; David J Sugarbaker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

8.  Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).

Authors:  Sujith R Kalmadi; Cathryn Rankin; Michael J Kraut; Andrew D Jacobs; Daniel P Petrylak; David J Adelstein; Mary Louise Keohan; Robert N Taub; Ernest C Borden
Journal:  Lung Cancer       Date:  2007-11-19       Impact factor: 5.705

9.  Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

Authors:  Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

10.  The clinicopathological characteristics with long-term outcomes in malignant mesothelioma.

Authors:  Mutlu Dogan; Gungor Utkan; Cemil Hocazade; Dogan Uncu; Serife Toptas; Nuriye Ozdemir; Nurullah Zengin; Fikri Icli
Journal:  Med Oncol       Date:  2014-09-11       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.